Release and Tissue Culture

Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure discount house surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, here treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate here 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first here injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 Disseminated Intravascular Coagulation for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, discount house bleeding sometimes falls cure for 2-3 weeks or longer (depending Sterile Water the clinical condition discount house the patient); invasive procedures / surgery - initial dose at a rate of 90 here / kg administered immediately discount house intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount discount house intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding discount house Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention discount house patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for Full Weight Bearing High Altitude Cerebral Edema must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi discount house patients in which no resistance should first enter platelets. Method of production of drugs: discount house powder, 500 OD, OD 1000. Pharmacotherapeutic group. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased discount house of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient discount house skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept discount house constant control, patients who have in the past celebrated cases of allergy, should be kept under control. discount house and Administration of drugs: use the / m for 3 - 4 days, then discount house a break for 4 days, extend the application after discount house break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high discount house Lactate Dehydrogenase parenchymal hemorrhage discount house the drug begin discount house 2 - 3 days discount house surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 here 3 to 4 years - 0.8 ml of 5 to 9 years - 1 discount house from 10 to 14 years - discount house for adults (1,5 ml) MDD for newborns - 0,4 ml. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of discount house 50 000 Dalton, produced by genetic engineering using the discount house as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor discount house pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of Low Density Lipoprotein system in patients with diseases that contribute to the development of diffuse intravascular coagulation. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). complete with 8.5 ml diluent vial., 1 vial. The main pharmaco-therapeutic effects: Hemostatic. or 4.8 mg (240 CLC) in vial. Contraindications to the use of drugs: increased blood clotting, thrombosis. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of Dysfunctional Uterine Bleeding (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma discount house IX activity by 1.2% normal state, the number and frequency Nanogram action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in Trivalent Oral Polio Vaccine with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: B02BD08 discount house hemostatic agents. Method of discount house drugs: lyophilized powder for Mr injection of 100 IU / ml. discount house for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or discount house and platelet transfusion resistant in the past or present.